A bubble manufacturing container of the present invention includes: a container body having an opening portion; and a rubber stopper provided on the opening portion of the container body. The rubber stopper is constituted so that the bubbles 1 of an inside of the container body are able to be taken by piercing an injection needle. It is preferred that the bubble manufacturing container has a fastening portion provided on the rubber stopper, having an opening and sealing the container body with the rubber stopper. Furthermore, it is preferred that the container body mounts a weight portion.

A protein nanocage formulation with enhanced mucus penetration capability and colloidal stability provides controlled delivery of therapeutic, prophylactic, or diagnostic agents to tumors. A dense coating of a surface altering agent such as polyethylene glycol on self-assembled protein nanocages enhances the rapid and uniform distribution of the formulation at mucosal tissues following topical administration, enhances circulation time following intravenous administration, and enhances penetration into hypoxic tumor cores. The density and the molecular weight of surface altering agents are selected to allow the protein nanocages to also bind to tumor cell receptors and release chemotherapeutic agents after tumor cell uptake. Agents delivered in the formulation have better efficacy compared to carrier-free agents. A method of making the protein nanocage formulation with enhanced mucus penetration and colloidal stability is also provided.

The present invention provides a delivery device for administration of active agent (12) containing compositions into the suprachoroidal space or supraciliary space. The invention provides methods of treatment of an ocular disease or condition accordingly. The invention also provides active agent containing compositions for delivery into the suprachoroidal space or supraciliary space.

Disclosed herein are low density particles comprising polymerized fibrin that are micrometer or nanometer sized in diameter. The particles can further include at least one therapeutic agent. The particles may be used to treat wounds, by administration directly or systemically to the site of the wound. Exemplary wounds that may be treated with the fibrin particles include a trauma wound, a surgical wound, a burn wound, or an ulcer wound. Also disclosed herein are methods for preparing the particles using a shearing process.

Provided herein are microencapsulated compositions, optionally oil-in-water emulsions, comprising one or more long chain polyunsaturated fatty acids (LCPUFAs), optionally in triglyceride form, wherein the encapsulant comprises one or more low molecular weight proteins. In particular embodiments the composition has a surface free fat content of about 1%. Also provided are methods for protecting one or more LCPUFAs, or one or more oils comprising the one or more LCPUFAs, from oxidative degradation, comprising encapsulating the LCPUFAs or oil with an encapsulant comprising one or more low molecular weight proteins.

This invention discloses methods and composition to form biodegradable polymer implant arrays in the live tissue. Artificial cavities are created in the live tissue by using laser ablation, oscillating needle, microneedle array and other methods. The cavities are then filled with biodegradable polymer solution. The solvent in the polymer solution is dissipated in the tissue to form a biodegradable polymer implant in artificial cavities. The cavities and implants formed are arranged to form of an array of implants. The biodegradable polymer in the cavity can also be loaded with drug to form biodegradable drug delivery array in the live tissue.

The present invention relates to dry particulate encapsulation compositions comprising a water-insoluble matrix comprising at least 70% by weight of proteins, based on the total weight of the matrix and a moisture content of about 5 to 10% by weight, based on the total weight of the matrix and an encapsulate encapsulated in the matrix, wherein the matrix once wetted in a clear colorless aqueous solution or in mineral oil has a lightness value (L*) greater than about 40, a color vividness or Chroma (C*) lower than about 33 and a hue angle between about 70 and 90. The encapsulation compositions of the present invention are useful in encapsulating dyes, medications and vitamins. Fine particulate encapsulation compositions comprising natural dyes can be used in lieu of artificial lakes in confectionery, cosmetics and caplets color coatings.

The present disclosure relates to a composition of albumin microbubbles to which are bound one or more moieties that exhibit a binding preference for the albumin microbubbles relative to free, native HSA. Production of the albumin microbubble composition and use of the albumin microbubble composition in ultrasound mediated delivery of therapeutic or diagnostic agents is also discussed.

The present invention relates to a method for improving lactic acid bacteria in survival rate, storage stability, resistance to acid or bile, and adherence to intestinal epithelial cells by coating the surface of lactic acid bacteria with silk fibroin, and a lactic acid bacteria composition prepared therethrough. Conventional techniques construct only a physical protective barrier outside a lactic acid bacteria body by multi-stage coating and thus retain the limitation of being unable to identify an effect on the coherence of lactic acid bacteria to intestinal epithelial cells upon the uptake of the lactic acid bacteria. In contrast, the present invention provides a method in which lactic acid bacteria is coated with silk fibroin extracted from cocoons, whereby the lactic acid bacteria is improved in stability under a storage and distribution condition as well as having remarkably increased stability and intestinal adherence particularly under an intestinal environment.

A composition for use in a method of providing sustained energy release over time in a subject is described. The composition comprises or consists of microparticles comprising high glycaemic index (Gl) carbohydrate contained within a gastric-resistant, ileal-sensitive, GLP-1 stimulative, non-porous carrier configured for release of the high Gl carbohydrate in the ileum, wherein the composition is administered orally to the subject.